A random forest model predicts responses to infliximab in Crohn’s disease based on clinical and serological parameters

作者：Yong Li, Jianfeng Pan, Nan Zhou, Dongni Fu, Guanghui Lian, Jun Yi, Yu Peng, Xiaowei Liu · 发表于：Scandinavian Journal of Gastroenterology · 年份：2021 · DOI：10.1080/00365521.2021.1939411 · 被引用次数：21 · 研究领域：Inflammatory Bowel Disease、Rheumatoid Arthritis Research and Therapies、Platelet Disorders and Treatments

Yong Lia , Jianfeng Pana , Nan Zhoua, Dongni Fua, Guanghui Liana, Jun Yia, Yu Penga* & Xiaowei Liuab* a Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha, Chinab Hunan International Scientific and Technological Cooperation Base of Artificial Intelligence Computer Aided Diagnosis and Treatment for Digestive Disease, Xiangya Hospital, Central South University, Changsha, ChinaSupplemental data for this article can be accessed here.CONTACT Yu Peng pengyu918@csu.edu.cn Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaXiaowei Liu liuxw@csu.edu.cn Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha, Hunan, China; Hunan International Scientific and Technological Cooperation Base of Artificial Intelligence Computer Aided Diagnosis and Treatment for Digestive Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaAbstractBackground Infliximab (IFX) has revolutionised the treatment for Crohn’s disease (CD) recently, while a part of patients show no response to it at the end of the induction period. We developed a random forest-based prediction tool to predict the response to IFX in CD patients.Methods This observational study retrospectively enrolled the patients diagnosed with active CD and received IFX treatment at the Gastroenterology Department in Xiangya Hospital of Central South University between January 2017 and December 2019. The baseline data...